Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB074 for neuropathic pain from lumbosacral radiculopathy
NL-OMON46236Phase 2Active, not recruiting
- Sponsor
- Biogen
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vixotrigine in lumbosacral radiculopathy (3 arms), sponsored by Biogen. Primary endpoint: Change in weekly average daily neuropathic pain score. Started Aug 2017; status: active, not recruiting.
02
Drugs
vixotrigine
03
Conditions
lumbosacral radiculopathy
Beyond the preview
Go deeper on NL-OMON46236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46236.